(Q39509894)

12 September 2017

Novel immunotherapy for metastatic bladder cancer using vaccine of human interleukin-2 surface-modified MB 49 cells (English)

1 reference

12 September 2017

1 reference

1 reference

Xinji Zhang

1

1 reference

12 September 2017

Xiaojun Shi

2

1 reference

12 September 2017

Jinlong Li

3

1 reference

12 September 2017

Zhiming Hu

4

1 reference

12 September 2017

Fangfang Guo

5

1 reference

12 September 2017

Xiao Huang

6

1 reference

12 September 2017

Zhehuan Zhang

7

1 reference

12 September 2017

Pengyu Sun

8

1 reference

12 September 2017

Yuming Jing

9

1 reference

12 September 2017

Jimin Gao

10

1 reference

12 September 2017

Wanlong Tan

11

1 reference

12 September 2017

language of work or name

English

0 references

publication date

13 July 2011

1 reference

12 September 2017

1 reference

12 September 2017

78

1 reference

12 September 2017

722.e1-722.e6

1 reference

12 September 2017

3

1 reference

The systemic treatment of advanced and metastatic bladder cancer.

12 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.04.044

7 January 2021

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.04.044

Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.04.044

IL-2 family of cytokines in T regulatory cell development and homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.04.044

A novel immunotherapy for superficial bladder cancer by the immobilization of streptavidin-tagged bioactive IL-2 on the biotinylated mucosal surface of the bladder wall.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.04.044

Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.04.044

Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.04.044

A novel immunotherapy for superficial bladder cancer by intravesical immobilization of GM-CSF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.04.044

Treatment of murine transitional cell carcinoma with intralesional interleukin 2 and murine interferon gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.04.044

Vaccination with allogeneic GM-CSF gene-modified lung cancer cells: antitumor activity comparing with that induced by autologous vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.04.044

Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.04.044

The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.04.044

Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.04.044

The allogeneic response and tumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.04.044

The dendritic cell system and its role in immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.04.044

10.1016/J.UROLOGY.2011.04.044

7 January 2021

Identifiers

DOI

1 reference

12 September 2017

1 reference